Request Free Sample Report Buy Report
Home > Reports > Acellular Therapy Market: Information by Application (Cardiology, Hepatology, Neurology), Scaffold (Cell Laden Hydrogel)

Acellular Therapy Market: Information by Application (Cardiology, Hepatology, Neurology), Scaffold (Cell Laden Hydrogel), Disease (Cancer, Parkinsons), and Region — Forecast till 2030

Published At : 28 Jul, 2022
Updated At : 29 Jul, 2022
Market Snapshot
Base Year:
2021
Study Period:
2020-2030
CAGR:
16.2 %
Fastest Growing Market:
Europe
Largest Market:
North America

The global acellular therapy market size was valued at USD 8.45 billion in 2021 and is projected to reach USD 32.60 billion by 2030 at a CAGR of 16.20% from 2022 to 2030. The capacity for regeneration among humans is limited. The purpose of regenerative medicine is to aid in the healing of an organism. Stem cell research has made tremendous strides, laying a solid foundation for its use in regenerative medicine applications involving injured or diseased tissues.

Stem cells (SCs) have been transplanted into the damaged tissue because SCs live in humans for their entire lives and can aid in the differentiation of new stem cells and differentiated cells. The transplantation of SCs has become a pillar of regenerative medicine. Intercellular communication between stem cells and differentiated cells has been a focal point of regenerative medicine.

Get more information on this report Download Sample Report

Market Dynamics

Drivers for the Acellular Therapy Market

  • Benefits From Paracrine Actions

Some stem cell therapies derive their benefits from paracrine actions as opposed to long-term engraftment and survival of transplanted cells. The advantages of stem cell therapy via paracrine actions have led to the development of a cell-free therapeutic technique, also known as acellular therapy.

Recent research has concentrated on developing alternatives to cell-based therapies involving paracrine elements. The use of soluble factors (secretome), extracellular vesicles, and mitochondrial transport can all be employed to generate "cell-free" stem cell therapies. Due to their ability to bypass biological barriers and facilitate the intercellular transmission of bioactive substances, EVs are currently being studied as potential cell-free therapeutic agents.

  • Benefits From Bone Tissue Engineering

The primary trends in acellular bone tissue engineering today are directed toward the creation of an ECM-based bioscaffold, typically by incorporating several key growth factors for mimicking the natural bone structure and establishing an environment for maintaining osteogenesis osteoconduction and osteoinduction.

  • EV As Therapeutic Medicines

The potential use of EVs as therapeutic agents in acellular regenerative medicine has gained considerable traction in recent years. In addition, extracellular vesicles are used to treat pathological conditions and to address the operational concerns of the acellular strategy.

EVs are a heterogeneous group of double-layered, lipid membrane-enclosed vesicles with distinct biophysical properties and functions in physiology and pathology. Due to their capacity to transport nucleic acids (including mRNAs and miRNAs), proteins, and lipids between cells, they are emerging as a crucial intercellular communication mediator. EVs are capable of communicating with target cells in numerous ways.

Restraints for the Acellular Therapy Market

  • Varying Results for Each Individual

As a result of their rapid degradation and diffusion into surrounding tissues, the targeted delivery of growth factors can be problematic. Due to the fact that the potency of each cytokine in a cocktail differs from its individual action, the synergistic or antagonistic effects of multiple cytokines on a given cell population must be evaluated in various in vivo settings. The manufacturing process and supply logistics of autologous cell-based therapy products are extraordinarily complex and impede their commercialisation. When addressing widespread diseases that affect millions of patients, such as Age-related Macular Degeneration (AMD), or when the number of cells required for therapy is significant, as in the case of severe burns, these limitations are especially significant.

Opportunities for the Acellular Therapy Market

The potential use of EVs as therapeutic agents in acellular regenerative medicine has gained significant traction in recent years. Additionally, extracellular vesicles are used to treat pathological conditions and meet the challenges and operational concerns of the acellular strategy.

MSC secretomes from diverse tissue origins can be encapsulated in various biomaterials. In a number of preclinical studies, the potential of such combinations was demonstrated during the healing of defects in periodontal tissue, alveolar bone, mandibular angles, calvarial bone, and maxillary sinus floor elevation. The effectiveness of such combinations for bone formation in age-related osteoporosis was also demonstrated.

 

Segmentation of the Acellular Therapy Market

The global market for acellular therapy is segmented by company, region (country), scaffolds and application. Utilising this report, players, stakeholders, and other market participants in the global Acellular Therapy market will have the upper hand. The segment analysis focuses on revenue and forecast by region (country), Type, and Application for the period 2022-2027.

 

Regional Analysis of the Acellular Therapy Market

Acellular Therapy Market Regional Analysis

Regional Growth Insights Request Sample Pages

North America is the most dominant market for acellular therapy globally. North America accounted for the largest revenue share and is anticipated to maintain its dominance. North America was the highest revenue contributor. North America is anticipated to hold a dominant share of the global Acellular therapy market. The growth of the North American Acellular Therapy Market is due to developed healthcare infrastructure, a more prominent target population, ease of drug availability, and favourable healthcare reimbursement policies. Countries like the United States of America spend heavily on the research and development of Acellular Therapies. This trend is followed by Europe and the Asia Pacific regions. In addition, the increase in the elderly population in most European countries and some Asian countries like Japan present significant opportunities for the growth of the market for Acellular Therapies.

EVs/exosomes have been implicated in a wide range of physiological functions, such as protein clearance, immunity, signalling, and even gene regulation, that are still largely uncharacterised. However, they have also been identified as crucial players in pathological processes. Thus, EVs/exosomes are implicated in infections and cancer and also appear to play a major role in neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease (AD), multiple sclerosis (MS), lysosomal storage disorders, amyotrophic lateral sclerosis, stroke, and prion disease, although this role has not yet been fully characterised. Involvement in such a large number of pathological and physiological functions makes extracellular vesicles (EVs) not only potential biomarkers of disease but also excellent candidates for the development of new cell-free (acellular) therapies.

Endogenous regenerative technology is the most dominant technology in the Acellular Therapy market. This includes regeneration with the help of stem cells.

Competitive Landscape

List of Top Acellular Therapy Market Companies Profiled

  • Evox Therapeutics Ltd
  • Exogenus Therapeutics
  • ArunA Biomedical
  • Exogenus Therapeutics
  • Aegle Therapeutics Corp
  • Invitrx Therapeutics Inc.
  • Capricor Therapeutics
  • Organicell Regenerative Medicine Inc.
  • EV Therapeutics Inc.
  • Codiak BioSciences Inc.
  • Rion LLC
  • Stem Cell Medicine Ltd.
  • Direct Biologics LLC.

 

Recent Developments

  • In May 2022, Belgian Cell therapy development company Bone Therapeutics entered into a non-binding term sheet and an exclusive discussion with the shareholders of Medsenic for a duration of three months.
  • In January 2022, Oxford Biomedica, a UK based gene and cell therapy group, entered into an agreement with Homology Medicines which is a US-based genetic medicines company, to establish a full scope, high-performing Adeno Associated virus (AAV) manufacturing and innovation business in the United States of America.
  • In 2019 Asterias Therapeutics merged with BioTime to build a leading cell therapy company.
  • Novartis acquired AveXis to strengthen its position on the market. Kymriah, owned by Novartis, is one of the first FDA-approved cell therapies. CellforCure, French contract development and manufacturing organisation (CDMO), began manufacturing Kymriah for Novartis by mid-2019 and was acquired by the company to address development and manufacturing deficiencies. The acquisition of AveXis provides Novartis with gene therapy expertise and a robust candidate pipeline.

 

Global Acellular Therapy Market: Segmentation

By Application

  • Cardiology
  • Hepatology
  • Neurology
  • Gastroenterology
  • Oncology

By Scaffold

  • Cell Laden Hydrogel
  • Selective Laser Sintering (SLS)
  • Fused Deposition Modelling (FDM)

By Disease

  • Cancer
  • Alzheimer's
  • Parkinsons
  • Sclerosis

By Region

  • North America (USA, Canada)
  • Europe (UK, Germany, France, Spain, Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Rest of the Asia Pacific)
  • Latin America, the Middle East and Africa (LAMEA) 
Table of Content Download Sample